[go: up one dir, main page]

ECSP14032516A - N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales - Google Patents

N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales

Info

Publication number
ECSP14032516A
ECSP14032516A ECIEPI201432516A ECPI201432516A ECSP14032516A EC SP14032516 A ECSP14032516 A EC SP14032516A EC IEPI201432516 A ECIEPI201432516 A EC IEPI201432516A EC PI201432516 A ECPI201432516 A EC PI201432516A EC SP14032516 A ECSP14032516 A EC SP14032516A
Authority
EC
Ecuador
Prior art keywords
quinolin
hetero
methyl
production
cyclohexil
Prior art date
Application number
ECIEPI201432516A
Other languages
English (en)
Inventor
Duy Nguyen
Benjamin Bader
Silke Köhr
Hermann Künzer (Fallecido)
Martin Fritsch
Gimenez Hortensia Faus
Original Assignee
Poli Nutri Alimentos S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14032516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Poli Nutri Alimentos S A filed Critical Poli Nutri Alimentos S A
Publication of ECSP14032516A publication Critical patent/ECSP14032516A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

La invención se relaciona con N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas, intermediarios y métodos para su producción, uso de las mismas para tratar y/o prevenir enfermedades y uso de las mismas para producir productos medicinales y uso de los mismos para tratar y/o prevenir enfermedades, en especial enfermedades hiperproliferativas.
ECIEPI201432516A 2012-06-26 2014-12-19 N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales ECSP14032516A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12004764 2012-06-26

Publications (1)

Publication Number Publication Date
ECSP14032516A true ECSP14032516A (es) 2015-12-31

Family

ID=48699019

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201432516A ECSP14032516A (es) 2012-06-26 2014-12-19 N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales

Country Status (40)

Country Link
US (1) US9428460B2 (es)
EP (1) EP2864291B1 (es)
JP (1) JP6181172B2 (es)
KR (1) KR20150023880A (es)
AP (1) AP3919A (es)
AR (1) AR091565A1 (es)
AU (1) AU2013283543B2 (es)
BR (1) BR112014032538A2 (es)
CA (1) CA2877786C (es)
CL (1) CL2014003443A1 (es)
CO (1) CO7170167A2 (es)
CR (1) CR20140593A (es)
CU (1) CU20140144A7 (es)
CY (1) CY1118412T1 (es)
DK (1) DK2864291T3 (es)
DO (1) DOP2014000295A (es)
EA (1) EA028063B1 (es)
EC (1) ECSP14032516A (es)
ES (1) ES2609455T3 (es)
HR (1) HRP20161745T1 (es)
HU (1) HUE032306T2 (es)
IL (1) IL236146B (es)
JO (1) JO3342B1 (es)
LT (1) LT2864291T (es)
MA (1) MA37700B1 (es)
ME (1) ME02590B (es)
MX (1) MX2014016054A (es)
NZ (1) NZ703100A (es)
PE (1) PE20150154A1 (es)
PH (1) PH12014502869B1 (es)
PL (1) PL2864291T3 (es)
PT (1) PT2864291T (es)
RS (1) RS55500B1 (es)
SG (1) SG11201408254UA (es)
SI (1) SI2864291T1 (es)
TN (1) TN2014000532A1 (es)
TW (1) TWI600646B (es)
UA (1) UA115447C2 (es)
UY (1) UY34881A (es)
WO (1) WO2014001247A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164374A1 (en) * 2014-04-22 2015-10-29 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20190004742A (ko) * 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN109414420A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328821A (en) 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU2001268040A1 (en) 2000-06-23 2002-01-08 Eli Lilly And Company Methods and compounds for inhibiting mrp1
KR100883731B1 (ko) 2001-06-22 2009-02-12 기린 파마 가부시끼가이샤 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
JP2006515014A (ja) 2003-01-30 2006-05-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド PKC−θのインヒビターとして有用な2,4−ジアミノピリミジン誘導体
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005094251A2 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2005117570A1 (en) 2004-05-27 2005-12-15 Jack Saffron Feeding dish to prevent pest infestation
MX2007005590A (es) 2004-11-09 2007-05-24 Smithkline Beecham Corp Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US20060293341A1 (en) 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives
US20090240070A1 (en) 2006-02-06 2009-09-24 Showa Denko K.K. Whitening dermatological preparations
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008064432A1 (en) 2006-12-01 2008-06-05 The University Of Sydney Polycyclic molecular compounds
WO2009023655A1 (en) 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Quinazolinedione chymase inhibitors
WO2009055053A2 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
JP5699075B2 (ja) 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
NZ597528A (en) 2009-07-21 2014-08-29 Gilead Sciences Inc Inhibitors of flaviviridae viruses
CA2773615A1 (en) 2009-09-11 2011-03-17 Arwed Cleve Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses

Also Published As

Publication number Publication date
JP6181172B2 (ja) 2017-08-16
EA201500039A1 (ru) 2015-06-30
MA37700B1 (fr) 2018-03-30
WO2014001247A1 (en) 2014-01-03
SG11201408254UA (en) 2015-01-29
EP2864291B1 (en) 2016-10-05
RS55500B1 (sr) 2017-05-31
IL236146B (en) 2018-05-31
PH12014502869A1 (en) 2015-02-23
PE20150154A1 (es) 2015-02-19
ES2609455T3 (es) 2017-04-20
BR112014032538A2 (pt) 2017-06-27
CA2877786A1 (en) 2014-01-03
SI2864291T1 (sl) 2017-01-31
TWI600646B (zh) 2017-10-01
CN104684896A (zh) 2015-06-03
CY1118412T1 (el) 2017-06-28
UY34881A (es) 2014-01-31
EP2864291A1 (en) 2015-04-29
AP3919A (en) 2016-11-30
IL236146A0 (en) 2015-02-01
HK1206346A1 (en) 2016-01-08
CO7170167A2 (es) 2015-01-28
TN2014000532A1 (en) 2016-03-30
US20150191431A1 (en) 2015-07-09
PH12014502869B1 (en) 2015-02-23
DK2864291T3 (en) 2017-01-16
AU2013283543A1 (en) 2015-01-29
JP2015521641A (ja) 2015-07-30
JO3342B1 (ar) 2019-03-13
MA20150269A1 (fr) 2015-08-31
ME02590B (me) 2017-06-20
TW201400460A (zh) 2014-01-01
CL2014003443A1 (es) 2015-06-26
PL2864291T3 (pl) 2017-07-31
AR091565A1 (es) 2015-02-11
AU2013283543B2 (en) 2017-11-02
UA115447C2 (uk) 2017-11-10
HRP20161745T1 (hr) 2017-02-24
NZ703100A (en) 2016-10-28
LT2864291T (lt) 2017-01-10
KR20150023880A (ko) 2015-03-05
MX2014016054A (es) 2015-04-10
CR20140593A (es) 2015-02-16
US9428460B2 (en) 2016-08-30
CU20140144A7 (es) 2015-08-27
AP2014008141A0 (en) 2014-12-31
PT2864291T (pt) 2017-01-06
EA028063B1 (ru) 2017-10-31
DOP2014000295A (es) 2015-01-31
HUE032306T2 (en) 2017-09-28
CA2877786C (en) 2020-08-25

Similar Documents

Publication Publication Date Title
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
CR20150370A (es) Compuestos antivirales
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
NI201500038A (es) Piridinonas bicíclicas novedosas
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
UY34660A (es) Inhibidores de benzodioxano de la producción de leucotrieno
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
MX2015001051A (es) Derivados de manosa, un proceso para su preparacion y sus usos como un farmaco.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
UY35746A (es) Derivados de fenilalanina sustituidos
ECSP14032516A (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
CL2016001495A1 (es) Espiro-oxazolonas.
UY34664A (es) Derivados de piridona y piridazinona como antagonistas de mch-1r, composiciones farmacéuticas y sus usos
UY34703A (es) Ciclobutilcarboxamidas, proceso para su preparación, composiciones pesticidas y composiciones farmacéuticas que las comprenden, y usos de las mismas como nematicidas
TWD180406S (zh) 拋棄式尿布
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina
CU20140058A7 (es) Nuevos 2h-indizoles como antagonistas del receptor ep-2
UY4423U (es) Pañal para adulto